Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for CRISPR Therapeutics AG (CRSP : NSDQ)

• Company Description    CRISPR Therapeutics AG is a leading gene editing company focused on developing CRISPR/Cas9-based therapeutics. The company is rapidly leveraging its CRISPR/Cas9 gene-editing platform to make therapies for the treatment of hemoglobinopathies, cancer, diabetes and other diseases. Number of Employees: 393

• Price / Volume Information    Yesterday's Closing Price: $53.07 Daily Weekly Monthly 20 Day Moving Average: 1,712,633 shares Shares Outstanding: 95.99 (millions) Market Capitalization: $5,093.94 (millions) Beta: 1.72 52 Week High: $78.48 52 Week Low: $30.04 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -0.82% 0.68% 12 Week 5.65% 2.05% Year To Date 1.20% 1.34%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL BAARERSTRASSE 14 - ZUG,V8 CH-6300 CHE ph: 41-41-561-3277 fax: - ir@crisprtx.com http://www.crisprtx.com

• General Corporate Information    Officers Samarth Kulkarni - Chief Executive Officer; Chairman and Director Raju Prasad - Chief Financial Officer Ali Behbahani - Director Maria Fardis - Director H. Edward Fleming - Director Peer Information CRISPR Therapeutics AG (CORR.) CRISPR Therapeutics AG (RSPI) CRISPR Therapeutics AG (CGXP) CRISPR Therapeutics AG (BGEN) CRISPR Therapeutics AG (GTBP) CRISPR Therapeutics AG (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: H17182108 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 12/01/25 Next Expected EPS Date: 05/05/26 Share - Related Items Shares Outstanding: 95.99 Most Recent Split Date: (:1) Beta: 1.72 Market Capitalization: $5,093.94 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.13 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-4.19 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 15.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 52.00% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 05/05/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.63 Price/Cash Flow: - Price / Sales: 1,451.26 EPS Growth vs. Year Ago Period: -211.36% vs. Previous Quarter: -17.09% Sales Growth vs. Year Ago Period: -97.58% vs. Previous Quarter: -2.81% ROE 12/31/25 - -26.31 09/30/25 - -21.23 06/30/25 - -20.05 ROA 12/31/25 - -22.30 09/30/25 - -18.06 06/30/25 - -17.09 Current Ratio 12/31/25 - 13.32 09/30/25 - 16.22 06/30/25 - 16.61 Quick Ratio 12/31/25 - 13.32 09/30/25 - 16.22 06/30/25 - 16.61 Operating Margin 12/31/25 - -13,827.52 09/30/25 - -1,022.63 06/30/25 - -976.47 Net Margin 12/31/25 - -16,569.77 09/30/25 - -1,273.70 06/30/25 - -1,229.43 Pre-Tax Margin 12/31/25 - -16,466.24 09/30/25 - -1,263.99 06/30/25 - -1,218.98 Book Value 12/31/25 - 20.17 09/30/25 - 21.07 06/30/25 - 19.81 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - 0.00 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - 0.00 09/30/25 - 0.00 06/30/25 - 0.00

Powered by Zacks Investment Research ©